In the absence of federal regulations and amid a patchwork of state regulations for cannabis products, epilepsy patients are using unapproved cannabidiol (CBD) without any clear direction on dosage or any knowledge of what is in their products, stakeholders told FDA at a public meeting Friday (May 31). Despite the potential risks, a representative from the Epilepsy Foundation argued FDA should let patients continue to buy the cheaper, more readily available alternatives to the only agency-approved CBD drug for epilepsy,…